论文部分内容阅读
[目的]探讨老年食管癌患者同步放化疗的耐受性。[方法]对符合根治性放化疗条件的老年(年龄≥65岁)食管癌患者给予60Gy/30f放疗并同步给予2个周期紫杉醇+顺铂方案化疗,观察生存情况及不良反应。[结果]66例(80.1%)患者完成计划放化疗,中位生存期17.38±1.68个月,44例(53.6%)患者出现3~5级不良反应,以血液学毒性、放射性食管炎、消化道毒性为最常见,治疗前体重下降、血红蛋白<8g/L和白蛋白<30g/L,患者耐受性差。[结论]经过选择的老年食管癌患者同步放化疗治疗效果好,安全可行。治疗前营养状况影响患者治疗耐受性。
[Objective] To investigate the tolerability of concurrent chemoradiation in elderly patients with esophageal cancer. [Methods] The elderly patients (≥65 years old) with esophageal cancer who underwent radical chemoradiotherapy were given 60Gy / 30f radiotherapy and two cycles of paclitaxel plus cisplatin were given concurrently to observe the survival and adverse reactions. [Results] 66 patients (80.1%) completed planned chemotherapy and radiotherapy, the median survival time was 17.38 ± 1.68 months, and 44 patients (53.6%) had grade 3 to 5 adverse reactions. The hematological toxicity, radiation esophagitis, Road toxicity is the most common, before treatment, weight loss, hemoglobin <8g / L and albumin <30g / L, poor patient tolerance. [Conclusion] The treatment of elderly patients with esophageal cancer with concurrent chemoradiotherapy has a good effect and is safe and feasible. Pretreatment nutritional status affects patient tolerability.